Myecfo LLC Buys New Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

Myecfo LLC purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 17,497 shares of the biotechnology company’s stock, valued at approximately $1,426,000. Arrowhead Pharmaceuticals accounts for approximately 0.5% of Myecfo LLC’s holdings, making the stock its 15th biggest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Citizens Financial Group Inc. RI purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $309,000. BlackRock Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth about $1,208,838,000. Pallas Capital Advisors LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth about $381,000. Deutsche Bank AG purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth about $12,165,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Arrowhead Pharmaceuticals during the second quarter valued at approximately $267,000. Institutional investors own 62.61% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ARWR shares. Sanford C. Bernstein boosted their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Stifel Nicolaus started coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective for the company. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Morgan Stanley boosted their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, B. Riley Financial upped their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $97.33.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock opened at $89.41 on Thursday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $19.56 and a twelve month high of $95.49. The firm has a market cap of $12.59 billion, a price-to-earnings ratio of -39.74 and a beta of 1.27. The business’s fifty day simple moving average is $82.33 and its two-hundred day simple moving average is $72.64. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. During the same quarter in the previous year, the firm posted ($1.26) EPS. The firm’s revenue for the quarter was up 171.0% on a year-over-year basis. Analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.